Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 1/20 | 0.60 |
| ▸ | DVL1 | O14640 | 1/20 | 0.38 |
| ▸ | DVL3 | Q92997 | 1/20 | 0.38 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10316154 | 1.00 | SMO (0.60) | SMODVL1DVL3ACSS2CNR1 | |
| SCHEMBL10316141 | 0.91 | SMO (0.55) | SMODVL1DVL3ACSS2ALDH1A1 | |
| SCHEMBL1063020 | 0.89 | SMO (0.68) | SMOACSS2ALDH1A1 | |
| SCHEMBL1063022 | 0.89 | SMO (0.68) | SMOACSS2ALDH1A1 | |
| SCHEMBL10004447 | 0.88 | SMO (0.76) | SMOKDM4EALDH1A1 | |
| SCHEMBL10316159 | 0.87 | SMO (0.52) | SMOACSS2ALDH1A1 | |
| SCHEMBL10316158 | 0.87 | SMO (0.52) | SMOACSS2ALDH1A1 | |
| SCHEMBL11976396 | 0.85 | SMO (0.52) | SMOALDH1A1 | |
| SCHEMBL12826284 | 0.83 | SMO (0.51) | SMOALDH1A1 | |
| SCHEMBL10316152 | 0.83 | SMO (0.51) | SMOALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927718-B2 | Fused heterocyclic ring derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-06 | — | — | US | disclosed |
| US-8927718-B2 | Fused heterocyclic ring derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-06 | — | — | US | disclosed |
| US-20120208794-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-16 | — | — | US | disclosed |
| US-20120208794-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208794-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | SMO, GLI1, SHH | SMO 1/4885DVL1 205/4885DVL3 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.